



Astec LifeSciences Ltd.

**Date:** 14<sup>th</sup> August, 2023

To,  
**BSE Limited**  
P. J. Towers, Dalal Street, Fort,  
Mumbai – 400 001

To,  
**National Stock Exchange of India Limited**  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (East), Mumbai - 400 051

**Ref.:** BSE Scrip Code No. “533138”

**Ref.:** “ASTEC”

**Sub.: Intimation / Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Pendency of litigation(s) or dispute(s)**

Dear Sir / Madam,

Pursuant to the recent amendments to Regulation 30 read with Para B of Part A of the Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (including any modification(s) / amendment(s) / re-enactment(s) thereto) (“the Listing Regulations”) read with the Circular issued by SEBI vide Ref. No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13<sup>th</sup> July, 2023, the details of pending litigations / disputes which meet the materiality thresholds as specified under Regulation 30(4)(i)(c) of the Listing Regulations.

Please take the same on your records.

Thanking you,

Yours faithfully,

**For Astec LifeSciences Limited**

**Tejashree Pradhan**  
**Company Secretary & Compliance Officer**  
**(FCS 7167)**

**Encl.: As above**



Regd. Office :  
“Godrej One”, 3<sup>rd</sup> Floor,  
Pirojshanagar, Eastern Express Highway,  
Vikhroli (East), Mumbai-400079,  
Maharashtra, India  
Telephone No.: 022- 25188010  
Fax No.: 022-22618289  
Email id: astecinfo@godrejastec.com  
Website: www.astecsls.com  
CIN : L99999MH1994PLC076236



**List of Litigation(s) or Dispute(s)  
which qualify the threshold limits specified under Regulation 30(4)(i)(c) of the  
SEBI (Listing Obligations and Disclosure Obligations) Regulations, 2015**

Appeal	Parties	Court / Tribunal	Issue	Period	Amount with Interest (in Rs.)
Appeal against OIO No: 74/SHH/PC/RGD/2015-16 dated 08.03.2016	Astec LifeSciences Limited vs. Principal Commissioner of Central Excise, Raigad Commissionerate	CESTAT, Mumbai	The dispute relates to recovery of Cenvat credit on inputs by invoking Rule 3(5) of Cenvat Credit Rules, 2004.	November 2009 to March 2014	50,31,58,895
Appeal against OIO No: 74/SHH/PC/RGD/2015-16 dated 08.03.2016.	Ashok Hiremath vs. Principal Commissioner of Central Excise, Raigad Commissionerate	CESTAT, Mumbai	The dispute relates to imposition of penalty under Rule 26(1) of Central Excise Rules, 2002.	November 2009 to March 2014	3,30,77,808
Writ Petition 2961 of 2016	Principal Commissioner of Central Excise, Raigad Commissionerate vs. Astec LifeSciences Limited	Bombay High Court	<p>DGCEI, Mumbai alleged that Astec, which is a 100% EOU situated at B-17, MIDC, Mahad in order to evade Central Excise Duty has clandestinely cleared the goods from EOU to consignees in Domestic Tariff Area (DTA) and in order to regularize the sale, Astec had issued invoices from their other factory situated at B-16, MIDC, Mahad.</p> <p>The case was settled by the Settlement Commission vide order no. F/No/222/ST/KNA/2014/SC(MB) dated 22.06.15. Order of the Settlement Commissioner was challenged by Department before Mumbai High Court vide Writ No.2961 of 2016.</p>	April 2009 to March 2014	57,27,03,213





Appeal against Order of Assessment of Tax under Central Sales Tax Act	Astec LifeSciences Limited vs. Deputy Commissioner Of Sales Tax	JSCT (Appeals)	Deputy Commissioner has issued a Demand order for non-submission of C-forms including Interest. The case is currently pending with JSCT (Appeals) and hearing is awaited.	F.Y. 2011-12	4,71,91,167
Appeal against order under Section 143(3) of the Income Tax Act, 1961	Astec LifeSciences Limited vs. Assessing Officer (IT)	CIT(A)	The Company has filed an appeal with CIT(A) in November 2017. This is in respect of Scrutiny Assessment Notice for: (i) Disallowance of depreciation related to Nufarm assets: Rs. 4,82,85,000/- (ii) Disallowance of depreciation on SAP: Rs. 56,33,558/- (iii) Disallowance of SAP maintenance: Rs. 6,92,906/- (iv) Disallowance of ESOP expenses: Rs. 56,53,511/-	AY 2017-18	3,70,79,002
Commercial Suit 0000031/ 2019	Nath Biogenes India Limited Vs. 1) Astec LifeSciences Limited and 2) Ashok V. Hiremath	Additional District Judge, Aurangabad	Suit has been filed by Nath Biogenes India Limited ("NBIL") for damages of Rs.65 Crore. The Company had supplied a product to NBIL, a company based in Aurangabad, Maharashtra in April 2007. Thereafter, NBIL alleged that the use of the Company's product caused a failure in germination of NBIL's cotton seeds resulting in losses worth Rs.65 Crore.	-	65,82,13,650

\*\*\*\*\*

